Stephen Hoffman
Director/Board Member at RESEARCH ALLIANCE CORP. II
Net worth: 2 057 $ as of 29/04/2024
Profile
Stephen J.
Hoffman was the founder of Somatogen, Inc. (founded in 1987) where he held the title of Vice President-Science & Technology from 1987 to 1990.
He currently holds multiple positions including Chairman at Apic Bio, Inc. (since 2021), Independent Director at Research Alliance Corp.
II (since 2021), Independent Director at Talphera, Inc. (since 2010), Director at Implicit Bioscience Ltd.
(since 2022), Director at Palleon Pharma, Inc., Director at Receptor Life Sciences, Inc. (since 2021), and Director at BYOMass, Inc. (since 2021).
Dr. Hoffman has previously served as Chief Executive Officer & Director at Aerpio Therapeutics, Inc., Chief Executive Officer & Director at Aerpio Pharmaceuticals, Inc. (2017-2019), Chairman at Bicycle Therapeutics Plc (2016-2019), Chairman at Allos Therapeutics, Inc. (2002-2012), Chairman at Anchiano Therapeutics Ltd.
(2018-2019), Director at Danforth Advisors LLC (2020-2021), Director at Sirtris Pharmaceuticals, Inc. (2004-2008), Managing Director at Skyline Management LLC (2007-2014), Independent Director at Genocea Biosciences, Inc. (2013-2017), Director at Concert Pharmaceuticals, Inc., Director at KAI Pharmaceuticals, Inc., Director at Proteon Therapeutics, Inc., Independent Director at Dicerna Pharmaceuticals, Inc. (2007-2021), Director at Helomics Corp., Director at Tolerx, Inc., Director at PPD Dermatology LLC, Director at Sutro Biopharma, Inc., Director at Palleon Pharmaceuticals, Inc., Director at Collegium Pharmaceutical, Inc., General Partner at TVM Capital GmbH (2003-2007), General Partner at TVM Capital Corp.
(2003-2007), and Vice President-Science & Technology at Baxter International, Inc. (1987-1990).
Dr. Hoffman holds a doctorate degree from Northwestern University and The University of Colorado School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
TALPHERA, INC.
0.01% | 25/04/2024 | 1,837 ( 0.01% ) | 2 057 $ | 29/04/2024 |
Stephen Hoffman active positions
| Companies | Position | Start |
|---|---|---|
| TALPHERA, INC. | Director/Board Member | 31/01/2010 |
| RESEARCH ALLIANCE CORP. II | Director/Board Member | 28/02/2021 |
BYOMass, Inc.
 BYOMass, Inc. Miscellaneous Commercial ServicesCommercial Services BYOMass, Inc. provides investment holding services. The company is headquartered in Sudbury, MA. | Director/Board Member | 26/10/2021 |
Receptor Life Sciences, Inc.
 Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | Director/Board Member | 17/03/2021 |
Apic Bio, Inc.
 Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | Chairman | 04/01/2021 |
Palleon Pharma, Inc.
 Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Director/Board Member | - |
Implicit Bioscience Ltd.
 Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | Director/Board Member | 30/09/2022 |
Former positions of Stephen Hoffman
| Companies | Position | End |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Director/Board Member | 27/12/2021 |
Danforth Advisors LLC
 Danforth Advisors LLC Miscellaneous Commercial ServicesCommercial Services Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Director/Board Member | 30/11/2021 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Stephen Hoffman
| Northwestern University | Doctorate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 6 |
|---|---|
| TALPHERA, INC. | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| SUTRO BIOPHARMA, INC. | Health Technology |
| BICYCLE THERAPEUTICS PLC | Health Technology |
| BAXTER INTERNATIONAL INC. | Health Technology |
| Private companies | 25 |
|---|---|
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Helomics Corp.
 Helomics Corp. Medical/Nursing ServicesHealth Services Helomics Corp. provides cancer care development and treatment consulting services. Its products include chemoFx, biospeciFx, geneFx colon and geneFx lung. It also offers research and development services. The company was founded in 1995 and is headquartered in Pittsburgh, PA. | Health Services |
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
TVM Capital Corp.
 TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Finance |
Skyline Management LLC
 Skyline Management LLC Investment ManagersFinance Skyline Management LLC (Skyline Management) is a venture capital firm founded in 1997 by John Gordon Freund. The firm is headquartered in Palo Alto, California. | Finance |
PPD Dermatology LLC
 PPD Dermatology LLC Pharmaceuticals: MajorHealth Technology PPD Dermatology LLC develops novel pharmaceutical products and proprietary medical therapies for the dermatology market. The company provides therapies for skin diseases. It was founded in 2006 and is headquartered in Waltham, MA. | Health Technology |
Proteon Therapeutics, Inc.
 Proteon Therapeutics, Inc. BiotechnologyHealth Technology Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001 and is headquartered in Waltham, MA. | Health Technology |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Somatogen, Inc.
 Somatogen, Inc. BiotechnologyHealth Technology Somatogen, Inc. develops specialty oxygen therapeutics. It is engaged in the research, clinical development and commercialization of genetically engineered recombinant human hemoglobin-based products. The company is located in Boulder, CO. | Health Technology |
Hovione Farmaciência SA
 Hovione Farmaciência SA Pharmaceuticals: MajorHealth Technology Hovione FarmaCiencia SA manufactures and distributes active pharmaceutical ingredients. Its services include contract manufacturing services, off-patent API products, proprietary product licensing, and supporting capabilities. The company was founded by Diane de Lancastre Houssemayne Du Boulay Villax, Ivan Villax, Nicholas de Horthy and Andrew Onody in 1959 and is headquartered in Loures, Portugal. | Health Technology |
Palleon Pharmaceuticals, Inc.
 Palleon Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA. | Commercial Services |
Palleon Pharma, Inc.
Palleon Pharma, Inc. BiotechnologyHealth Technology Palleon Pharma, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA. | Health Technology |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Anchiano Therapeutics Ltd.
 Anchiano Therapeutics Ltd. BiotechnologyHealth Technology Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel. | Health Technology |
Danforth Advisors LLC
Danforth Advisors LLC Miscellaneous Commercial ServicesCommercial Services Danforth Advisors LLC provides advisory services. It offers finance support and stratigic consultation services for life science firm. The company was founded by Gregg Beloff and Daniel Geffken and is headquartered in Southborough, MA. | Commercial Services |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
Apic Bio, Inc.
Apic Bio, Inc. Packaged SoftwareTechnology Services Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA. | Technology Services |
Research Alliance Corp. II
 Research Alliance Corp. II Financial ConglomeratesFinance Research Alliance Corp. II operates as a blank check company. The company was founded by Peter Kolchinsky, Matthew Hammond and Tess Cameron on July 17, 2020 and is headquartered in Las Vegas, NV. | Finance |
Receptor Life Sciences, Inc.
Receptor Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Receptor Life Sciences, Inc. operates as a pharmaceutical development company. It offer treatment of pain, central nervous systems, metabolic disorders, and gastrointestinal disorders. The company was founded in 2015 and is headquartered in Seattle, WA. | Health Technology |
BYOMass, Inc.
BYOMass, Inc. Miscellaneous Commercial ServicesCommercial Services BYOMass, Inc. provides investment holding services. The company is headquartered in Sudbury, MA. | Commercial Services |
Implicit Bioscience Ltd.
Implicit Bioscience Ltd. BiotechnologyHealth Technology Implicit Bioscience Ltd. operates as a clinical-stage immunotherapy drug development company. It develops drugs that modulate the host immune response to disease. The firm develops small molecule dipeptide oglufanide disodium for community and hospital-acquired infections including those caused by bio-threat agents. The company was founded by Garry Llewellyn Redlich, Peter Ronald Andrews and Ian Hector Frazer and is headquartered in Woolloongabba, Australia. | Health Technology |
- Stock Market
- Insiders
- Stephen Hoffman
